KDM2B and cancer: KDM2B silencing is also reported to increase levels of tumor‐suppressing miRNA let‐7b, thereby downregulating EZH2 and reducing the entry into S‐phase and thus cancer growth (Karoopongse et al., 2014; Tzatsos et al., 2011).